Join to view full profile
800 Washington StBoston, MA 02111
Phone+1 617-636-8148
Fax+1 203-863-4738
Dr. Pai is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2003 - 2005
Harvard Medical SchoolClass of 2001
Certifications & Licensure
HI State Medical License 2024 - 2028
MA State Medical License 2013 - 2026
NY State Medical License 2004 - 2012
CT State Medical License 2005 - 2008
American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy Start of enrollment: 2022 Jan 03
- NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer Start of enrollment: 2020 Nov 24
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Plasma-based next generation sequencing in advanced non-small cell lung cancer (NSCLC): significance in diagnosis and treatment in Asian patients.Cherng-Horng Wu, Xia Wu, Xiao Hu, Alice Kennedy, Lori Pai
BMC Cancer. 2025-11-22 - Palliative and end-of-life care in Asian and White patients with metastatic lung cancer.Xiao Hu, John W Melson, Stacey S Pan, Yana V Salei, Lori Pai
The Oncologist. 2025-05-08 - 3 citationsReal-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors.Xiao Hu, Angie Mae Rodday, Anastasia Gurinovich, Stacey Pan, Yana V Salei
Immunotherapy. 2025-04-01
Press Mentions
- Neuroimmunological Adverse Events Associated with Immune Checkpoint Inhibitor: A Retrospective, Pharmacovigilance Study Using FAERS DatabaseJanuary 9th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
